2 assets in Nasal Cavity Adenocarcinoma

Therapeutic assets addressing Nasal Cavity Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Nasal Cavity Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Nasal Cavity Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)